About: Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19
Creator	Daniels, Lisa Sagardia, Lisa
Source	Medline; PMC
abstract	PURPOSE: Successful use of alteplase and argatroban to treat a patient with coronavirus disease 2019 (COVID-19)–associated massive pulmonary embolism with cardiac arrest is reported. SUMMARY: This case report describes a 42-year-old male with COVID-19 who developed a massive pulmonary embolism resulting in cardiac arrest after suspected failure of low-molecular-weight heparin therapy for a deep venous thrombosis. Administration of two 50-mg doses of intravenous alteplase resulted in return of spontaneous circulation, and low-dose argatroban was used as follow-up anticoagulation therapy without complications. This is the first case report of use of argatroban in a patient with COVID-19 with cardiac arrest–associated massive pulmonary embolism after failure of previous anticoagulation efforts. CONCLUSION: Argatroban may be used as an alternate anticoagulation strategy in COVID-19 patients who fail low-molecular weight therapy. A risk versus benefit discussion should be had regarding appropriateness of therapy as well as dosing. More data is needed to understand the unique hypercoagulable condition in COVID-19 patients as well as research that further highlights the role of argatroban and bivalirudin therapy in this patient population.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1093/ajhp/zxaa287
bibo:pmid	32780853
has license	no-cc
schema:url	https://doi.org/10.1093/ajhp/zxaa287
resource representing a document's title	Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19
has PubMed Central identifier	PMC7454294
has PubMed identifier	32780853
schema:publication	Am J Health Syst Pharm
resource representing a document's body	covid:PMC7454294#body_text
is schema:about of	named entity 'pulmonary embolism' named entity 'COVID-19' named entity 'bivalirudin' named entity 'nebulized' named entity 'airway support' named entity 'off-label' named entity 'paralysis' named entity 'aPTT' named entity 'risk factors' named entity 'hypoxemia' named entity 'HIT' named entity 'intravascular' named entity 'aPTT' named entity 'LMWH' named entity 'mucolytics' named entity 'critically ill' named entity 'guaifenesin' named entity 'steady state' named entity 'antiarrhythmic' named entity 'COVID-19' named entity 'COVID-19' named entity 'tranexamic acid' named entity 'albuterol' named entity 'infection' named entity 'emergency department' named entity 'mechanical ventilation' named entity 'anticoagulation' named entity 'aPTT' named entity 'Coagulation' named entity 'major bleeding' named entity 'ventricular tachycardia' named entity 'return of spontaneous circulation' named entity 'medical history' named entity 'Fibrinogen' named entity 'hypercoagulable state' named entity 'China' named entity 'Argatroban' named entity 'thrombolysis' named entity 'HIT' named entity 'HIT' named entity 'cardiopulmonary resuscitation' named entity 'unfractionated heparin' named entity 'enoxaparin' named entity 'acute coronary syndromes' named entity 'prothrombin time' named entity 'coagulation' named entity 'anticoagulation' named entity 'VTE' named entity 'alteplase' named entity 'argatroban' named entity 'hydroxychloroquine' named entity 'ICU' named entity 'coagulation abnormalities' named entity 'antithrombin' named entity 'cardiopulmonary resuscitation' named entity 'VTE' named entity 'pharmacologic' named entity 'subcutaneously' named entity 'DVT' named entity 'anticoagulation' named entity 'ng/mL' named entity 'thrombophilia' named entity 'thrombolytic therapy' named entity 'enoxaparin' named entity 'DVT' named entity 'argatroban' named entity 'DIC' named entity 'titrating' named entity 'aPTT' named entity 'heparin-induced thrombocytopenia' named entity 'Child-Pugh score' named entity 'body weight' named entity 'hypercoagulable' named entity 'LMWH' named entity 'Mechanical ventilation' named entity 'anticoagulation' named entity 'hemoptysis' named entity 'hemoptysis' named entity 'COVID-19' named entity 'aPTT' named entity 'Fio2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software